Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment...

ver descrição completa

Detalhes bibliográficos
Autores: Martínez Bosch, Neus, Vilariño, Noelia, Alameda, Francesc, Mojal, Sergi, Arumí Uria, Montserrat, Carrato, Cristina, Aldecoa Ansórregui, Iban, Ribalta Farrés, Teresa María, Vidal, Noemí, Bellosillo, Beatriz, Menéndez, Silvia, Barco, Sonia del, Gallego, Oscar, Pineda, Estela, López Martos, Raquel, Hernández, Ainhoa, Mesia Barroso, Carlos, Esteve Codina, Anna, Iglesia, Núria de la, Balañá, Carme, Martínez García, María, Navarro, Pilar
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2023
País:España
Recursos:Universidad de Barcelona
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/200923
Acesso em linha:https://hdl.handle.net/2445/200923
Access Level:Acceso aberto
Palavra-chave:Glioma
Tumors cerebrals
Gliomas
Brain tumors
Descrição
Resumo:Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The beta-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.

Registros relacionados